{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:48:55Z","timestamp":1760122135318},"reference-count":143,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.rmr.2011.06.017","type":"journal-article","created":{"date-parts":[[2012,1,5]],"date-time":"2012-01-05T00:59:36Z","timestamp":1325725176000},"page":"161-177","source":"Crossref","is-referenced-by-count":2,"title":["Th\u00e9rapeutiques antiangiog\u00e9niques dans le cancer bronchique\u00a0: indications et toxicit\u00e9s"],"prefix":"10.1016","volume":"29","author":[{"given":"C.","family":"Cl\u00e9ment-Duch\u00eane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Godbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Martinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2011.06.017_bib0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.rmr.2011.06.017_bib0015","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1378\/chest.111.6.1710","article-title":"Revisions in the International System for Staging Lung Cancer","volume":"111","author":"Mountain","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2011.06.017_bib0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.13-S1-37","article-title":"Systemic treatment for advanced (stage IIIb\/IV) non-small cell lung cancer: more treatment options\u00a0; more things to consider. Conclusion","volume":"13","author":"Bunn","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.rmr.2011.06.017_bib0025","doi-asserted-by":"crossref","unstructured":"Depierre A, Lagrange JL, Theobald S, et al. Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000). Br J Cancer 2003;89:S35\u201349.","DOI":"10.1038\/sj.bjc.6601083"},{"key":"10.1016\/j.rmr.2011.06.017_bib0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/JTO.0b013e3181c59a60","article-title":"Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review","volume":"5","author":"Clement-Duchene","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0035","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.2005.10.022","article-title":"Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions","volume":"23","author":"Gasparini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-007-0022-4","article-title":"Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors","volume":"8","author":"Cabebe","year":"2007","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0045","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1634\/theoncologist.2008-0108","article-title":"Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC","volume":"13","author":"Herbst","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.rmr.2011.06.017_bib0050","doi-asserted-by":"crossref","unstructured":"Wakelee H. Antibodies to vascular endothelial growth factor in non-small cell lung cancer. J Thorac Oncol 2008;3:S113\u2013118.","DOI":"10.1097\/JTO.0b013e318174e993"},{"key":"10.1016\/j.rmr.2011.06.017_bib0055","doi-asserted-by":"crossref","unstructured":"Wakelee HA, Schiller JH. Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin Lung Cancer 2005;7:S31\u201338.","DOI":"10.3816\/CLC.2005.s.005"},{"key":"10.1016\/j.rmr.2011.06.017_bib0060","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/JTO.0b013e318187220f","article-title":"Targeting angiogenesis in the treatment of lung cancer","volume":"3","author":"Wheatley-Price","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0065","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2011.06.017_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1573394052952456","article-title":"Targeting established tumor vasculature: a novel approach to cancer treatment","volume":"1","author":"Kelland","year":"2005","journal-title":"Current Cancer Therapy Treatment"},{"key":"10.1016\/j.rmr.2011.06.017_bib0075","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"Engl J N Med"},{"key":"10.1016\/j.rmr.2011.06.017_bib0080","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular permeability factor, an endothelial cell mitogen related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.rmr.2011.06.017_bib0085","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000468622","article-title":"Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis","volume":"49","author":"Pepper","year":"1996","journal-title":"Enzyme Protein"},{"key":"10.1016\/j.rmr.2011.06.017_bib0090","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1242\/jcs.114.5.853","article-title":"The splice variants of vascular endothelial growth factor (VEGF) and their receptors","volume":"114","author":"Robinson","year":"2001","journal-title":"J Cell Sci"},{"key":"10.1016\/j.rmr.2011.06.017_bib0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2005.09.005","article-title":"Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood","volume":"51","author":"Bremnes","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2011.06.017_bib0100","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nm1101-1194","article-title":"Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth","volume":"7","author":"Lyden","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.rmr.2011.06.017_bib0105","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0110","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0115","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Gray R, Schiller JH. ECOG 4599\u00a0phase III trial of carboplatin and paclitaxel_bevacizumab: subset analysis of survival by gender. J Clin Oncol 2006; 24:abstract 7036.","DOI":"10.1200\/jco.2006.24.18_suppl.7036"},{"key":"10.1016\/j.rmr.2011.06.017_bib0120","unstructured":"Wakelee HA, Dahlberg SE, Brahmer JR. Increased benefit from bevacizumab (BEV) in younger women with advanced NSCLC on Eastern Cooperative Oncology Group (ECOG) E4599. J Thorac Oncol 2008; 3:abstract 131."},{"key":"10.1016\/j.rmr.2011.06.017_bib0125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1634\/theoncologist.12-6-713","article-title":"FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.rmr.2011.06.017_bib0130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1078-0432.CCR-09-2439","article-title":"Bevacizumab safety in patients with central nervous system metastases","volume":"16","author":"Besse","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0135","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1200\/JCO.2009.22.0616","article-title":"Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases","volume":"27","author":"Socinski","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0140","first-page":"1487","article-title":"First-line Bevacizumab combined with Cisplatin\/Gencitabine (CG) in patients (pts) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC): AVAIL (BO17704), a phase III randomized study","volume":"12","author":"Reck","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0145","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0150","first-page":"1487","volume":"12","author":"Hainsworth","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0155","doi-asserted-by":"crossref","unstructured":"Kabbinavar FF, Miller VA, Johnson BE, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:15s. (suppl; abstract 7526).","DOI":"10.1200\/jco.2010.28.15_suppl.7526"},{"key":"10.1016\/j.rmr.2011.06.017_bib0160","doi-asserted-by":"crossref","unstructured":"Davila E, Lilenbaum R, Raez L. Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24:abstract 17009.","DOI":"10.1200\/jco.2006.24.18_suppl.17009"},{"key":"10.1016\/j.rmr.2011.06.017_bib0165","doi-asserted-by":"crossref","unstructured":"Heist RS, Fidias P, Huberman M. Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:abstract 7700.","DOI":"10.1200\/jco.2007.25.18_suppl.7700"},{"key":"10.1016\/j.rmr.2011.06.017_bib0170","doi-asserted-by":"crossref","unstructured":"Kraut MJ. Phase II study of gemcitabine and carboplatin plus bevacizumab for stage III\/IV non-small cell lung cancer: preliminary safety data. J Clin Oncol 2006; 24:abstract 17091.","DOI":"10.1200\/jco.2006.24.18_suppl.17091"},{"key":"10.1016\/j.rmr.2011.06.017_bib0175","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2008.20.8181","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer","volume":"27","author":"Patel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0180","doi-asserted-by":"crossref","unstructured":"Waples JM, Auerbach M, Boccia R. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer. J Clin Oncol 2007; 25:abstract 18025.","DOI":"10.1200\/jco.2007.25.18_suppl.18025"},{"key":"10.1016\/j.rmr.2011.06.017_bib0185","doi-asserted-by":"crossref","unstructured":"William WN, Kies MS, Fossella FV. Phase II study of bevacizumab in combination with doc\u00e9taxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:abstract 18098.","DOI":"10.1200\/jco.2007.25.18_suppl.18098"},{"key":"10.1016\/j.rmr.2011.06.017_bib0190","doi-asserted-by":"crossref","unstructured":"Gandara D, Kim ES, Herbst RS. S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol 2009; 27:abstract 8015.","DOI":"10.1200\/jco.2009.27.15_suppl.8015"},{"key":"10.1016\/j.rmr.2011.06.017_bib0195","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.nephro.2008.10.002","article-title":"Vascular and renal effects of anti-angiogenic therapy","volume":"4","author":"Halimi","year":"2008","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.rmr.2011.06.017_bib0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2007.13.1144","article-title":"Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599","volume":"26","author":"Ramalingam","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0205","doi-asserted-by":"crossref","unstructured":"Leighl NB, Zatloukal P, Mezger J. Efficacy and safety of first-line bevacizumab (Bv) and cisplatin\/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704\u00a0study (AVAiL). J Clin Oncol 2009;27:abstract 8050.","DOI":"10.1200\/jco.2009.27.15_suppl.8050"},{"key":"10.1016\/j.rmr.2011.06.017_bib0210","doi-asserted-by":"crossref","unstructured":"Akerley W, Hainsworth J, Oh Y. Safety of bevacizumab therapy in subjects with brain metastases due to non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:abstract PD463-3-3.","DOI":"10.1097\/01.JTO.0000283413.15497.7a"},{"key":"10.1016\/j.rmr.2011.06.017_bib0215","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JTO.0b013e3181f94ad4","article-title":"BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab+carboplatin\/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer","volume":"6","author":"Hainsworth","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0220","doi-asserted-by":"crossref","first-page":"379S","DOI":"10.1200\/JCO.2005.01.8267","volume":"24","author":"Fehrenbacher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0225","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2146\/ajhp080455","article-title":"Understanding and managing the possible adverse effects associated with bevacizumab","volume":"66","author":"Shord","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.rmr.2011.06.017_bib0230","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rmr.2011.06.017_bib0235","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Available at www.nccn.org."},{"key":"10.1016\/j.rmr.2011.06.017_bib0240","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0245","doi-asserted-by":"crossref","unstructured":"Thanigaimani S, Mangoni A, Karapetis CS, et al. Anti-VEGF drugs, endothelial dysfunction, and hypertension: Is there a relationship? J Clin Oncol 2010;28:abstract 13585.","DOI":"10.1200\/jco.2010.28.15_suppl.e13585"},{"key":"10.1016\/j.rmr.2011.06.017_bib0250","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000262450","article-title":"Antiangiogenic drugs in oncology: a focus on drug safety and the elderly\u00a0\u2013\u00a0a mini-review","volume":"56","author":"Boehm","year":"2010","journal-title":"Gerontology"},{"key":"10.1016\/j.rmr.2011.06.017_bib0255","series-title":"Principles and practice of oncology","article-title":"Complications of vascular endothelial growth factor inhibitors in colorectal cancer","author":"Starling","year":"2005"},{"key":"10.1016\/j.rmr.2011.06.017_bib0260","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.rmr.2011.06.017_bib0265","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","article-title":"Managing patients treated with bevacizumab combination therapy","volume":"69","author":"Gordon","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.rmr.2011.06.017_bib0270","doi-asserted-by":"crossref","unstructured":"Li I, Stitt L, Whiston F, Alkhayyat SS, et al. Wound complications in neoadjuvant versus adjuvant treatment of operable rectal cancer (ORC). J Clin Oncol 2010; 28:abstract14099.","DOI":"10.1200\/jco.2010.28.15_suppl.e14099"},{"key":"10.1016\/j.rmr.2011.06.017_bib0275","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1634\/theoncologist.11-1-85","article-title":"Bevacizumab-induced nasal septum perforation","volume":"11","author":"Fakih","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.rmr.2011.06.017_bib0280","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.bjc.6605828","article-title":"Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients","volume":"103","author":"Mailliez","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.rmr.2011.06.017_bib0285","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.rmr.2011.06.017_bib0290","doi-asserted-by":"crossref","unstructured":"Hapani S, Ranpura V, Wu S. Risk of fatal adverse events with bevacizumab in cancer patients treated with chemotherapy: A meta-analysis. J Clin Oncol 2010; 28:abstract19500.","DOI":"10.1200\/jco.2010.28.15_suppl.e19500"},{"key":"10.1016\/j.rmr.2011.06.017_bib0295","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(10)70151-0","article-title":"Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4\u00a0study","volume":"11","author":"Crino","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0300","unstructured":"Braehmer J, Spigel D, Garst JL, et al. The impact of tumor histology on effectiveness in bevacizumab (BV) treated patients (PTS) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a BV obserational cohort study (OCS). Ann Oncol 2010;21;viii122\u201361, 426P."},{"key":"10.1016\/j.rmr.2011.06.017_bib0305","unstructured":"Fischbach NA, Wozniak A, Kumar P, et al. Clinical outcomes (COS) by sex in non-small cell lung cancer (NSCLC) patients (PTS): preliminary results from ARIES, a bevacizumab (BV) observational cohort study (OCS). Ann Oncol 2010;21;viii122\u201361, 425P."},{"key":"10.1016\/j.rmr.2011.06.017_bib0310","unstructured":"Soria JC, Mauguen A, Reck M, et al. Meta-analysis of randomized phase II\/III trials adding bevacizumab to platin-based chemotherapy as 1ST-line treatment in patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2010;21;viii122\u201361, 437P."},{"key":"10.1016\/j.rmr.2011.06.017_bib0315","doi-asserted-by":"crossref","unstructured":"Camidge DR, Eckhardt SG, Diab S. A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1\u00a0monoclonal antibody (Mab), in patients (pts) with advanced cancer. J Clin Oncol 2006;24:abstract 3032.","DOI":"10.1200\/jco.2006.24.18_suppl.3032"},{"key":"10.1016\/j.rmr.2011.06.017_bib0320","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O\u2019Reilly","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.rmr.2011.06.017_bib0325","first-page":"138","article-title":"Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer","volume":"28","author":"Yang","year":"2006","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.rmr.2011.06.017_bib0330","doi-asserted-by":"crossref","unstructured":"Sun Y, Wang J, Liu Y. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2005;23:abstract 7138.","DOI":"10.1200\/jco.2005.23.16_suppl.7138"},{"key":"10.1016\/j.rmr.2011.06.017_bib0335","doi-asserted-by":"crossref","first-page":"191126","DOI":"10.1200\/jco.2008.26.15_suppl.19126","article-title":"Rh-endostatin Injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: Randomized, double-blind, placebo-controlled, multicentre study","volume":"26","author":"Han","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0340","doi-asserted-by":"crossref","unstructured":"Massarelli E, Miller VA, Leighl NB. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2\u00a0weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA). J Clin Oncol 2007;18S:Abstract 7627.","DOI":"10.1200\/jco.2007.25.18_suppl.7627"},{"key":"10.1016\/j.rmr.2011.06.017_bib0345","unstructured":"A study of Aflibercept versus placebo in patients with second-line Doc\u00e9taxel for locally advanced or metastatic non-small-cell lung cancer. Available at: http:\/\/clinicaltrials.gov. Last updated 04\/13\/2009."},{"key":"10.1016\/j.rmr.2011.06.017_bib0350","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736\u00a0in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0355","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2008.20.8355","article-title":"Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study","volume":"27","author":"Schiller","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0360","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","article-title":"AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2\u00a0tyrosine kinase inhibitor for the treatment of cancer","volume":"65","author":"Wedge","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0365","doi-asserted-by":"crossref","unstructured":"Goss GD, Laurie S, Shepherd F. Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G\/C) in patients with advanced non-small cell lung cancer (ANSCLC): a study of the NCIC Clinical Trials Group. J Clin Oncol 2007;25:abstract 7649.","DOI":"10.1200\/jco.2007.25.18_suppl.7649"},{"key":"10.1016\/j.rmr.2011.06.017_bib0370","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1200\/JCO.2007.14.4741","volume":"26","author":"Laurie","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0375","unstructured":"Laurie SA, Arnold A, Shepherd FA. Overall survival [OS] results of NCIC Clinical Trials Group [CTG] BR.24: a randomized, double-blind trial of carboplatin+paclitaxel [C+P] with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer [NSCLC]. J Thorac Oncol 2009;4:S353:abstract C1.1."},{"key":"10.1016\/j.rmr.2011.06.017_bib0380","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2006.07.8170","article-title":"Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors","volume":"25","author":"Rosen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0385","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1097\/01.JTO.0000283417.64982.90","article-title":"Safety and pharmacokinetics (PK) of AMG 706\u00a0with carboplatin\/paclitaxel (C\/P) and\/or panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC)","volume":"2","author":"Blumenschein","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0390","doi-asserted-by":"crossref","unstructured":"Crawford J, Burris H, Stein M. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine\/cisplatin (GC) for the treatment of advanced solid malignancies. J Clin Onco 2006;24:Abtract 13005.","DOI":"10.1200\/jco.2006.24.18_suppl.13005"},{"key":"10.1016\/j.rmr.2011.06.017_bib0395","unstructured":"Study to evaluate AMG 706\u00a0with or without Carboplatin\/Paclitaxel or Panitumumab in the treatment of subjects with advanced non-small cell lung cancer (NSCLC) (MONET). Available at: http:\/\/clinicaltrials.gov. Last updated 04\/13\/2009."},{"key":"10.1016\/j.rmr.2011.06.017_bib0400","doi-asserted-by":"crossref","unstructured":"Blumenschein GR, Kabbinavar FF, Menon H, et al. Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P\/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:15s.(suppl; abstract 7528).","DOI":"10.1200\/jco.2010.28.15_suppl.7528"},{"key":"10.1016\/j.rmr.2011.06.017_bib0405","doi-asserted-by":"crossref","unstructured":"Nikolinakos P, Altorki N, Guarino MJ. Analyses of plasma cytokine\/angiogenic factors (C\/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer. J Clin Oncol 2008;26:abstract 7568.","DOI":"10.1200\/jco.2008.26.15_suppl.7568"},{"key":"10.1016\/j.rmr.2011.06.017_bib0410","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Soraf\u00e9nib (BAY 43-9006\u00a0Nexavar (R)), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0415","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006\u00a0exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0420","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Soraf\u00e9nib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2011.06.017_bib0425","doi-asserted-by":"crossref","unstructured":"Llovet J, Ricci S, Mazzaferro V. Soraf\u00e9nib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007;25:abstract LBA1. 2007.","DOI":"10.1200\/jco.2007.25.18_suppl.lba1"},{"key":"10.1016\/j.rmr.2011.06.017_bib0430","doi-asserted-by":"crossref","unstructured":"Adjei AA, Molina JR, Hillman SL. A front-line window of opportunity phase II study of soraf\u00e9nib in patients with advanced non-small cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 2007;25:abstract 7547.","DOI":"10.1200\/jco.2007.25.18_suppl.7547"},{"key":"10.1016\/j.rmr.2011.06.017_bib0435","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-06-2889","article-title":"Phase I trial of soraf\u00e9nib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer","volume":"13","author":"Adjei","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0440","doi-asserted-by":"crossref","unstructured":"Gatzemeier U, Blumenschein G, Fossella F. Phase II trial of single-agent soraf\u00e9nib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006;24:abstract 7002.","DOI":"10.1200\/jco.2006.24.18_suppl.7002"},{"key":"10.1016\/j.rmr.2011.06.017_bib0445","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3816\/CLC.2007.n.023","article-title":"A randomized phase II study of soraf\u00e9nib\/gemcitabine or soraf\u00e9nib\/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics","volume":"8","author":"Gridelli","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.rmr.2011.06.017_bib0450","doi-asserted-by":"crossref","unstructured":"Gutierrez M, Kummar S, Allen DS. A phase II study of multikinase inhibitor soraf\u00e9nib in patients with relapsed non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26:abstract 19084.","DOI":"10.1200\/jco.2008.26.15_suppl.19084"},{"key":"10.1016\/j.rmr.2011.06.017_bib0455","doi-asserted-by":"crossref","unstructured":"Schiller JH, Lee JW, Hanna NH. A randomized discontinuation phase II study of soraf\u00e9nib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol 2008;26:abstract 8014.","DOI":"10.1200\/jco.2008.26.15_suppl.8014"},{"key":"10.1016\/j.rmr.2011.06.017_bib0460","unstructured":"Dingemans AMC, van Wijk A, Hochstenbag M. Soraf\u00e9nib in pretreated patients with advanced non-small lung cancer harbouring a K-ras mutation. J Thorac Oncol 2009;4:S414\u20135:abstract D106."},{"key":"10.1016\/j.rmr.2011.06.017_bib0465","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","article-title":"Phase III study of carboplatin and paclitaxel alone or with soraf\u00e9nib in advanced non-small-cell lung cancer","volume":"28","author":"Scagliotti","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0470","unstructured":"Gatzemeier U, Eisen T, Santoro A, et al. Soraf\u00e9nib (S)+gemcitabine\/cisplatin (GC) VS GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): Phase III NSCLC research experience utilizing soraf\u00e9nib (NEXUS) trial. Ann Oncol 2010;21;viii1\u20132, LBA16."},{"key":"10.1016\/j.rmr.2011.06.017_bib0475","doi-asserted-by":"crossref","unstructured":"Adjei AA, Mandrekar S, Marks RS. A Phase I study of BAY 43-9006\u00a0and gefitinib in patients with refractory or recurrent nonsmall- cell lung cancer (NSCLC). J Clin Oncol 2005;23:abstract 3067.","DOI":"10.1200\/jco.2005.23.16_suppl.3067"},{"key":"10.1016\/j.rmr.2011.06.017_bib0480","doi-asserted-by":"crossref","unstructured":"Spigel DR, Anthony Greco F, Burris III HA. A randomized double-blind placebo-controlled phase II trial of soraf\u00e9nib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Thorac Oncol 2009;4:S355:abstract D1.5.","DOI":"10.1158\/1538-7445.AM10-LB-77"},{"key":"10.1016\/j.rmr.2011.06.017_bib0485","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.bjc.6605346","article-title":"Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer","volume":"101","author":"Novello","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.rmr.2011.06.017_bib0490","unstructured":"Raymond E, Faivre S, Vera K. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-traget tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 2003;22:abstract 769."},{"key":"10.1016\/j.rmr.2011.06.017_bib0495","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1200\/JCO.2007.13.9303","article-title":"Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer","volume":"26","author":"Socinski","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0500","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.lungcan.2010.01.016","article-title":"Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study","volume":"70","author":"Reck","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2011.06.017_bib0505","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/JTO.0b013e3181c7307e","article-title":"Safety and efficacy of combining sunitinib with bevacizumab+paclitaxel\/carboplatin in non-small cell lung cancer","volume":"5","author":"Socinski","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0510","unstructured":"Scagliotti G, Krzakowski M, Szczesna A, et al. Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced\/metastatic non-small cell lung cancer (NSCLC): A phase III study. Ann Oncol 2010;21;viii1\u20132, LBA6."},{"key":"10.1016\/j.rmr.2011.06.017_bib0515","first-page":"1546","article-title":"Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase","volume":"9","author":"Ciardiello","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0520","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/annonc\/mdn674","article-title":"An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer","volume":"20","author":"De Boer","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0525","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2006.10.5122","article-title":"Randomized, placebo-controlled phase II study of vandetanib plus doc\u00e9taxel in previously treated non small-cell lung cancer","volume":"25","author":"Heymach","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0530","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdi247","article-title":"Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors","volume":"16","author":"Holden","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0535","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2008.18.6015","article-title":"Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study","volume":"27","author":"Natale","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0540","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus doc\u00e9taxel versus doc\u00e9taxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3\u00a0trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0545","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/07357900902744528","article-title":"Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma","volume":"27","author":"Harshman","year":"2009","journal-title":"Cancer Invest"},{"key":"10.1016\/j.rmr.2011.06.017_bib0550","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","article-title":"Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial","volume":"29","author":"De Boer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0555","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","article-title":"Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer","volume":"29","author":"Natale","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0560","unstructured":"Drvs J, Mross D, Medinger M. Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK78\/ZK 222584 (PTK\/ZK) in patients with liver metastases. Proc Am Soc Clin Oncol 2003;22:abstract 1142."},{"key":"10.1016\/j.rmr.2011.06.017_bib0565","doi-asserted-by":"crossref","unstructured":"Gauler TC, Besse B, Meric JB. Phase II open-label study to investigate efficacy and safety of PTK787\/ZK 222584 (PTK\/ZK) orally administered once daily or twice daily at 1,250mg as second-line monotherapy in patients (pts) with stage IIIB\/IV non-small cell lung cancer (NSCLC). J Clin Oncol ASCO 2007;25:abstract 7541.","DOI":"10.1097\/01.JTO.0000283188.24297.13"},{"key":"10.1016\/j.rmr.2011.06.017_bib0570","doi-asserted-by":"crossref","unstructured":"Morgan B, Horsfield MA, Stattaus J. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787\/ZK 222584 (PTK\/ZK) as second-line mono-therapy in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:abstract 7676.","DOI":"10.1200\/jco.2007.25.18_suppl.7676"},{"key":"10.1016\/j.rmr.2011.06.017_bib0575","doi-asserted-by":"crossref","unstructured":"Camidge DR, Conkling P, Stephenson JJ, et al. Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26:abstract 3567.","DOI":"10.1200\/jco.2008.26.15_suppl.3567"},{"key":"10.1016\/j.rmr.2011.06.017_bib0580","doi-asserted-by":"crossref","unstructured":"Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol 2008;3:S131\u20134.","DOI":"10.1097\/JTO.0b013e318174e910"},{"key":"10.1016\/j.rmr.2011.06.017_bib0585","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","article-title":"Thrombotic events in patients with cancer receiving antiangiogenesis agents","volume":"27","author":"Zangari","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0590","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1078-0432.CCR-05-1571","article-title":"trial of soraf\u00e9nib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer","volume":"12","author":"Siu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0595","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/annonc\/mdn047","article-title":"Remission of diabetes while on sunitinib treatment for renal cell carcinoma","volume":"19","author":"Templeton","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0600","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cncr.23460","article-title":"Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor","volume":"112","author":"Khakoo","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2011.06.017_bib0605","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.clon.2007.03.014","article-title":"Vascular damaging agents","volume":"19","author":"Patterson","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.rmr.2011.06.017_bib0610","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2613.2002.00211.x","article-title":"The biology of the combretastatins as tumour vascular targeting agents","volume":"83","author":"Tozer","year":"2002","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0615","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1158\/1078-0432.CCR-05-1939","article-title":"5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent","volume":"12","author":"McKeage","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0620","first-page":"3304","article-title":"Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice","volume":"59","author":"Ching","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0625","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1005908805527","article-title":"Role of nitric oxide in angiogenesis and microcirculation in tumors","volume":"17","author":"Fukumura","year":"1998","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.rmr.2011.06.017_bib0630","first-page":"5537","article-title":"Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown","volume":"50","author":"Mahadevan","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0635","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2009.03.027","article-title":"Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid\/DMXAA) 1800mg\/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer","volume":"65","author":"McKeage","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2011.06.017_bib0640","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/sj.bjc.6604808","article-title":"Randomised phase II study of ASA404\u00a0combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer","volume":"99","author":"McKeage","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.rmr.2011.06.017_bib0645","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/sj.bjc.6600992","article-title":"Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent","volume":"88","author":"Jameson","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.rmr.2011.06.017_bib0650","unstructured":"ASA404\u00a0or placebo in combination with paclitaxel and carboplatin as first-line treatment for stage IIIB\/IV non-small cell lung cancer. Available at: http:\/\/clinicaltrials.gov. Last updated 04\/13\/2009."},{"key":"10.1016\/j.rmr.2011.06.017_bib0655","unstructured":"A Study of ASA404\u00a0or placebo in combination with doc\u00e9taxel in second-line treatment for (stage IIIB\/IV) non-small cell lung cancer. Available at: http:\/\/clinicaltrials.gov. Last updated 04\/13\/2009."},{"key":"10.1016\/j.rmr.2011.06.017_bib0660","doi-asserted-by":"crossref","unstructured":"Hida T, Takeda K, Daga H, et al. A safety and tolerability study of vadimezan in combination with doc\u00e9taxel in Japanese patients with advanced or recurrent solid tumors. J Clin Oncol 2010;28:abstract13106.","DOI":"10.1200\/jco.2010.28.15_suppl.e13106"},{"key":"10.1016\/j.rmr.2011.06.017_bib0665","first-page":"3142","article-title":"Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester)","volume":"46","author":"Kerr","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0670","first-page":"3408","article-title":"A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4\u00a0phosphate on a single-dose intravenous schedule in patients with advanced cancer","volume":"62","author":"Dowlati","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2011.06.017_bib0675","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2003.05.185","article-title":"Phase I clinical trial of weekly combretastatin A4\u00a0phosphate: clinical and pharmacokinetic results","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0680","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1200\/JCO.2003.12.986","article-title":"Phase I trial of the antivascular agent combretastatin A4\u00a0phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow","volume":"21","author":"Stevenson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0685","unstructured":"Gadgeel SM, LoRusso PM, Wozniak AJ. A dose-escalation study of the novel vascular targeting agent, ZD6126\u00a0in patients with solid tumors. Proc Am Soc Clin Oncol 2002;abstract 438."},{"key":"10.1016\/j.rmr.2011.06.017_bib0690","unstructured":"Radema SA, Beerepoot LV, Wittevee PO. Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage. Proc Am Soc Clin Oncol 2002;abstract 439."},{"key":"10.1016\/j.rmr.2011.06.017_bib0695","doi-asserted-by":"crossref","unstructured":"Dragnev KH, Rigas JR, Disalvo WM. A phase I trial of ABT-751\u00a0and carboplatin (C) in patients (pts) with previously treated non-small cell lung cancer (NSCLC). J Clin Oncol 2006;abstract 17098.","DOI":"10.1200\/jco.2006.24.18_suppl.17098"},{"key":"10.1016\/j.rmr.2011.06.017_bib0700","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JTO.0b013e318174e01f","article-title":"A phase II study of ABT-751\u00a0in patients with advanced non-small cell lung cancer","volume":"3","author":"Mauer","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0705","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1200\/JCO.2009.21.9733","article-title":"Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0710","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jnci\/djp200","article-title":"Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial","volume":"101","author":"Lee","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.rmr.2011.06.017_bib0715","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2007.11.8109","article-title":"Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04\u00a0IFCT 00-01","volume":"25","author":"Pujol","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2011.06.017_bib0720","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1349-7006.2000.tb01022.x","article-title":"TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death","volume":"91","author":"Otani","year":"2000","journal-title":"Jpn J Cancer Res"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842511015257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842511015257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T11:17:14Z","timestamp":1640344634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842511015257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":143,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0761842511015257"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2011.06.017","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}